Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 77, Issue 2, 2007, Pages 210-214

  Usui, Isao ^a   Fujisaka, Shiho ^a   Yamazaki, Katsuya ^a   Takano, Atsuko ^b   Murakami, Shiho ^c   Yamazaki, Yu ^b   Urakaze, Masaharu ^a   Hachiya, Haruo ^d   Takata, Michiyo ^d   Senda, Satoko ^e   Iwata, Minoru ^a   Satoh, Akira ^a   Sasaoka, Toshiyasu ^a   AK, Norel Dim ^a   Temaru, Rie ^f   Kobayashi, Masashi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Saiseikai Takaoka Hospital   (Japan)

^c Itoigawa General Hospital   (Japan)

^d Himi Citizen Hospital   (Japan)

^e TOYAMA RED CROSS HOSPITAL   (Japan)

^f Nanto Citizen Hospital   (Japan)

Author keywords

ARB; HOMA IR; Leptin; Telmisartan

Indexed keywords

ADIPOCYTOKINE; ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; TELMISARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; EXERCISE; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC DIET; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LEPTIN; LIPIDS; MALE; MIDDLE AGED;

EID: 34147213152     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.11.014     Document Type: Article

References (18)

1. Pollare T., Lithell H., and Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 321 (1989) 868-873
2. Iimura O., Shimamoto K., Matsuda K., Masuda A., Takizawa H., Higashiura K., et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am. J. Hypertens. 8 (1995) 353-357
3. Henriksen E.J., Jacob S., Kinnick T.R., Teachey M.K., and Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38 (2001) 884-890
4. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
5. Sleight P., Yusuf S., Pogue J., Tsuyuki R., Diaz R., and Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 358 (2001) 2130-2131
6. Kjeldsen S.E., Dahlof B., Devereux R.B., Julius S., Aurup P., Edelman J., et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
7. Degl'Innocenti A., Elmfeldt D., Hansson L., Breteler M., James O., Lithell H., et al. Cognitive function and health-related quality of life in elderly patients with hypertension--baseline data from the study on cognition and prognosis in the elderly (SCOPE). Blood Press. 11 (2002) 157-165
8. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
9. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
10. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
11. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
12. Derosa G., Cicero A.F., Bertone G., Piccinni M.N., Fogari E., Ciccarelli L., et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin. Ther. 26 (2004) 1228-1236
13. Vitale C., Mercuro G., Castiglioni C., Cornoldi A., Tulli A., Fini M., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 4 (2005) 6
14. Honjo S., Nichi Y., Wada Y., Hamamoto Y., and Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diab. Care 28 (2005) 498
15. Miura Y., Yamamoto N., Tsunekawa S., Taguchi S., Eguchi Y., Ozaki N., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diab. Care 28 (2005) 757-758
16. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest. 106 (2000) 467-472
17. Pershadsingh H.A., and Kurtz T.W. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diab. Care 27 (2004) 1015
18. Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., and Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47 (2006) 1003-1009